Maxim Group Downgrades Titan Pharmaceuticals (TTNP) to Hold, Following Earnings
Tweet
Share
E-mailGet Alerts TTNP Hot Sheet
Price: $6.97 --0%
Rating Summary:
0 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
0 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy downgraded Titan Pharmaceuticals (NASDAQ: TTNP) from Buy to Hold.
For an analyst ratings summary and ratings history on Titan Pharmaceuticals click here. For more ratings news on Titan Pharmaceuticals click here.
Shares of Titan Pharmaceuticals closed at $0.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
- Barclays Downgrades Li Auto (LI) to Equalweight
- Truist Securities Double Downgrades Monster Beverage (MNST) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maxim Group, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
